Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study
S. Saji, T. Yamashita, Junji Tsurutani, Y. Sagara et autres
jp (code pays fourni par la source)
0 citations
ESMO Open